ClinicalTrials.gg
CompletedNCT03919448Updated Jul 27, 2023Results posted

A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab

A Phase 1 interventional study of Bevacizumab in Pharmacokinetics and Safety Issues, sponsored by Laboratorios Richmond S.A.C.I.F.. Completed at 1 site in Argentina. Open to male participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Laboratorios Richmond S.A.C.I.F. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
Male
01

Study summary

The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two already marketed formulations of Bevacizumab Avastin® (reference product) and Cizumab® (Indian origin), to establish similarity.

Read the detailed description

Three-way bridge phase 1 trial. It is conducted in healthy, male adult subjects, it is single-dose, double-blind, parallel groups, randomized and balanced.

Blood samples are collected for up to 90 days, to determine serum drug concentration and anti-drug antibodies. Safety and tolerability are also assessed.

02

Conditions studied

  • Pharmacokinetics
  • Safety Issues

Keywords

  • Bevacizumab
  • Biosimilar
  • Antineoplastic Agents
  • Bioequivalence
  • Immunogenicity
  • safety
  • healthy male volunteers
03

In context

Lead sponsor

Laboratorios Richmond S.A.C.I.F. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study subjects must be willing and able to provide written
  • Subjects of study, volunteers, adults, healthy.
  • Study subjects whose safety and complementary laboratory tests are within normal values or which, in the Investigator's opinion, do not have clinical relevance: blood count, erythrosedimentation, hepatogram, urea, creatinine, glucose, coagulogram, serology for , , , complete urinalysis, detection of drugs of abuse in urine and .
  • Sample taken for immunogenicity
  • between 19 and 27 kg / m2 at the screening visit.
  • Subjects of study preferably non-smokers.
  • Men with a partner of childbearing age must agree that their partner uses an adequate method before entering the study and for at least 3 months after the end of the study. It is understood as a contraceptive method suitable to any hormonal contraceptive method or intrauterine device (which should be established before the start of the study) and the use of a spermicide as a barrier method. The use of a barrier method alone or sexual abstinence is not considered adequate.
  • Subjects must agree not to donate sperm during the study and for 4 months after treatment.

Exclusion criteria

Exclusion Criteria:

  • History of pulmonary, gastrointestinal, hepatic, renal, hematological, endocrine-metabolic, neurological or psychiatric illnesses (depressive disorders, in particular) at the time of taking the anamnesis and the physical examination during the first visit of the Protocol of Clinical research.
  • History of gastrointestinal surgeries (except uncomplicated appendectomy, at least 3 months old).
  • History of major surgery, surgical and / or history of significant trauma within 1 month of the screening visit.
  • Specifically, pre-existing gastrointestinal conditions such as abdominal fistulas, gastrointestinal perforation within 6 months of the screening visit.
  • Specifically, preexisting gastrointestinal conditions such as acute or subacute intestinal occlusion.
  • Specifically, history of inflammatory bowel disease.
  • History of hemorrhagic diseases and / or coagulopathies and / or thromboembolic events.
  • History of heart and vascular diseases: specifically myocardial infarction, unstable angina, cerebrovascular accident, uncontrolled arterial hypertension and cardiac arrhythmias.
  • Background or current history of alcohol or drug abuse.
  • Blood donation within 3 months prior to selection.
  • Administration of any other drug under investigation or participation in a clinical research trial within 3 months prior to the planned participation in this Clinical Research Protocol.
  • History of diseases or disorders that, in the opinion of the Investigator, may impede the participation of the study subject for safety reasons or that may influence the results of the same as well as the ability of the study subject to participate in the Clinical Research Protocol.
  • History of to bevacizumab and / or any of the .
  • Study subjects who present to therapy
  • Study subjects who have received (2 weeks before) or are receiving aspirin or clopidogrel
  • The study subjects must have suspended any pharmacological treatments at least 2 weeks before the initiation of this Clinical Research Protocol.
  • Non-cooperative study subjects
  • Study subjects employed by the Researcher or the Clinical-Pharmacokinetic Research Unit, with direct participation in the Clinical Research Protocol or other clinical protocols under the Direction of the Researcher or the Clinical-Pharmacokinetic Research Unit
  • Physical findings and laboratory analyses:
  • Cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, endocrine-metabolic, neurological disease or psychiatric disorder (depressive disorders, in particular)
  • Evidence of ulcers, unhealed wounds or bone fractures.
  • Clinically significant abnormalities in any laboratory analysis, and
  • Positive serology for , ,
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Active comparator
    Zutrab® (Bevacizumab Richmond)

    a single 1 mg/kg IV dose of Bevacizumab

    Biological: Bevacizumab

  • Active comparator
    Avastin®

    a single 1 mg/kg IV dose of Bevacizumab

    Biological: Bevacizumab

  • Active comparator
    Cizumab®

    a single 1 mg/kg IV dose of Bevacizumab

    Biological: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Peak Serum Concentration of Bevacizumab (Cmax)

    Cmax will be obtained directly from the serum concentration-time curve

    Time frame: 0, 0.33, 0.5, 1, 1.5 hours during infusion, 0.33, 0.66, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 336, 504, 672, 840, 1008, 1176, 1344, 1512 hours post-infusion

  2. Area Under the Serum Concentration-time Curve of Bevacizumab (ABC0-t)

    Area under the serum concentration-time curve from time zero to the last experimental point, will be calculated by the trapezoidal rule

    Time frame: Day 1 to Day 63

  3. Area Under the Serum Concentration- Time Curve ob Bevacizumab (ABC0-∞)

    Area under the serum concentration- time curve from time zero to infinity

    Time frame: Day 1 to Day 63

Secondary outcomes

  1. Time to Reach the Peak Serum Concentration (Tmax)

    Time to reach the peak serum concentration, which will be obtained directly from the serum concentration curve- time

    Time frame: Day 1 to Day 63

  2. Terminal Elimination Rate Constant (λz)

    Terminal elimination rate constant will be calculated by linear regression analysis of the semi-logarithmic curve

    Time frame: Day 1 to Day 63

  3. Elimination Half Life (T1/2)

    To assess pharmacokinetic parameters

    Time frame: Day 1 to Day 63

  4. Systemic Clearance (CL)

    To assess pharmacokinetic parameters

    Time frame: Day 1 to Day 63

  5. Distribution Volume

    To assess pharmacokinetic parameters

    Time frame: Day 1 to Day 63

  6. Number of Participants With Positive Anti-bevacizumab Serum Antibodies Detection

    To assess the immunogenic potential of the products under investigation, samples were taken for the determination of anti-bevacizumab serum antibodies for each randomized volunteer subject.

    Time frame: Screening and end of study (Day 63)

07

Results

Posted Jul 27, 2023

Participant flow

Participant flow — Overall Study
MilestoneZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Started303030
Completed293030
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryPeak Serum Concentration of Bevacizumab (Cmax)

Cmax will be obtained directly from the serum concentration-time curve

Time frame:
0, 0.33, 0.5, 1, 1.5 hours during infusion, 0.33, 0.66, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, 168, 336, 504, 672, 840, 1008, 1176, 1344, 1512 hours post-infusion
Reported as:
Mean · ng/ml
Peak Serum Concentration of Bevacizumab (Cmax)
ng/mlZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Peak Serum Concentration of Bevacizumab (Cmax)22144.83 ± 5550.0721540 ± 438222566.67 ± 8368.14
Statistical analysis
  • Zutrab® (Bevacizumab Richmond) vs Avastin® · ANOVA · p = 0.9766 (Power of ANOVA: 0,93) · Hazard ratio (hr): 101.55 · 90% CI 90.19 to 114.34
  • Avastin® vs Cizumab® · ANOVA · p = 0.9766 (Power of ANOVA: 0,93) · Hazard ratio (hr): 100.95 · 90% CI 89.75 to 113.55
  • Zutrab® (Bevacizumab Richmond) vs Cizumab® · ANOVA · p = 0.9766 · Hazard ratio (hr): 100.59 · 90% CI 88.16 to 114.77
PrimaryArea Under the Serum Concentration-time Curve of Bevacizumab (ABC0-t)

Area under the serum concentration-time curve from time zero to the last experimental point, will be calculated by the trapezoidal rule

Time frame:
Day 1 to Day 63
Reported as:
Mean · h*ng/ml
Area Under the Serum Concentration-time Curve of Bevacizumab (ABC0-t)
h*ng/mlZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Area Under the Serum Concentration-time Curve of Bevacizumab (ABC0-t)5153367.55 ± 1276468.145641733.72 ± 1160626.125500141.94 ± 1849362.76
Statistical analysis
  • Zutrab® (Bevacizumab Richmond) vs Avastin® · ANOVA · p = 0.3617 (Power of ANOVA: 0,95) · Hazard ratio (hr): 90.82 · 90% CI 81.21 to 101.57
  • Avastin® vs Cizumab® · ANOVA · p = 0.3617 (Power of ANOVA: 0.95) · Hazard ratio (hr): 94.87 · 90% CI 84.91 to 105.99
  • Zutrab® (Bevacizumab Richmond) vs Cizumab® · ANOVA · p = 0.3617 · Hazard ratio (hr): 95.73 · 90% CI 84.82 to 108.05
PrimaryArea Under the Serum Concentration- Time Curve ob Bevacizumab (ABC0-∞)

Area under the serum concentration- time curve from time zero to infinity

Time frame:
Day 1 to Day 63
Reported as:
Mean · h.ng/ml
Area Under the Serum Concentration- Time Curve ob Bevacizumab (ABC0-∞)
h.ng/mlZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Area Under the Serum Concentration- Time Curve ob Bevacizumab (ABC0-∞)5374225.878 ± 1340507.115919875.18 ± 1276082.305777584.241 ± 1951347.40
Statistical analysis
  • Zutrab® (Bevacizumab Richmond) vs Avastin® · ANOVA · p = 0.3529 (Power of ANOVA: 0.94) · Hazard ratio (hr): 90.46 · 90% CI 80.64 to 101.47
  • Avastin® vs Cizumab® · ANOVA · p = 0.3529 (Power of ANOVA: 0.94) · Hazard ratio (hr): 95.02 · 90% CI 84.80 to 106.49
  • Zutrab® (Bevacizumab Richmond) vs Cizumab® · ANOVA · p = 0.3529 · Hazard ratio (hr): 95.19 · 90% CI 84.17 to 107.67
SecondaryTime to Reach the Peak Serum Concentration (Tmax)

Time to reach the peak serum concentration, which will be obtained directly from the serum concentration curve- time

Time frame:
Day 1 to Day 63
Reported as:
Mean · h
Time to Reach the Peak Serum Concentration (Tmax)
hZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Time to Reach the Peak Serum Concentration (Tmax)9.34 ± 11.6516.69 ± 22.795.64 ± 7.46
SecondaryTerminal Elimination Rate Constant (λz)

Terminal elimination rate constant will be calculated by linear regression analysis of the semi-logarithmic curve

Time frame:
Day 1 to Day 63
Reported as:
Mean · 1/h
Terminal Elimination Rate Constant (λz)
1/hZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Terminal Elimination Rate Constant (λz)0.002 ± 0.0010.002 ± 0.0010.002 ± 0.001
SecondaryElimination Half Life (T1/2)

To assess pharmacokinetic parameters

Time frame:
Day 1 to Day 63
Reported as:
Mean · h
Elimination Half Life (T1/2)
hZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Elimination Half Life (T1/2)352.19 ± 173.17344.58 ± 82.04371.86 ± 315.65
SecondarySystemic Clearance (CL)

To assess pharmacokinetic parameters

Time frame:
Day 1 to Day 63
Reported as:
Mean · ml/h/kg
Systemic Clearance (CL)
ml/h/kgZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Systemic Clearance (CL)0.20 ± 0.050.18 ± 0.040.19 ± 0.06
SecondaryDistribution Volume

To assess pharmacokinetic parameters

Time frame:
Day 1 to Day 63
Reported as:
Mean · ml/kg
Distribution Volume
ml/kgZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Distribution Volume99.10 ± 51.3985.35 ± 17.6297.91 ± 67.17
SecondaryNumber of Participants With Positive Anti-bevacizumab Serum Antibodies Detection

To assess the immunogenic potential of the products under investigation, samples were taken for the determination of anti-bevacizumab serum antibodies for each randomized volunteer subject.

Time frame:
Screening and end of study (Day 63)
Reported as:
Number · participants tested positive for ADA
Number of Participants With Positive Anti-bevacizumab Serum Antibodies Detection
participants tested positive for ADAZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
Screening001
End of study000

Adverse events

Collected over Adverse events were evaluated and recorded during the 63 days of the clinical study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zutrab® (Bevacizumab Richmond)0/29 (0%)0/29 (0%)12/29 (41.4%)
Avastin®0/30 (0%)0/30 (0%)13/30 (43.3%)
Cizumab®0/30 (0%)0/30 (0%)10/30 (33.3%)
Most frequent other events
Most frequent other events
EventZutrab® (Bevacizumab Richmond)Avastin®Cizumab®
DiarrheaGastrointestinal disorders7/296/303/30
Abdominal painGastrointestinal disorders6/295/304/30
HeadacheNervous system disorders4/291/303/30
VomitingGastrointestinal disorders4/292/301/30
NauseaGastrointestinal disorders2/290/301/30
Blurry visionEye disorders0/292/300/30
EpistaxisRespiratory, thoracic and mediastinal disorders0/290/301/30

Baseline characteristics

Age, Customized
Age, Customized(Participants)Zutrab® (Bevacizumab Richmond)Avastin®Cizumab®Total
21 to 55 years29303089
Sex: Female, Male
Sex: Female, Male(Participants)Zutrab® (Bevacizumab Richmond)Avastin®Cizumab®Total
Female0000
Male29303089
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Zutrab® (Bevacizumab Richmond)Avastin®Cizumab®Total
Count of participants———0
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Zutrab® (Bevacizumab Richmond)Avastin®Cizumab®Total
Mean24.05 (19.56 to 26.94)24.06 (19.01 to 26.99)24.85 (19.23 to 26.91)24.32 (19.01 to 26.99)
08

Study locations

1 site
  • FP Clinical Pharma S.R.L.
    Buenos Aires, C1425BAA, Argentina
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Sep 2019, 5 months.

Results were first posted in Jul 2023, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2019
First posted
Apr 18, 2019
StartActual
Apr 1, 2019
Primary completionActual
Sep 11, 2019
CompletionActual
Sep 11, 2019
Results first posted
Jul 27, 2023
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03919448
Lead sponsor
Laboratorios Richmond S.A.C.I.F.
Collaborators
FP Clinical Pharma S.R.L., Syngene
Responsible party
Sponsor
First posted
Apr 18, 2019
Start date
Apr 1, 2019
Primary completion
Sep 11, 2019
Completion
Sep 11, 2019
Results posted
Jul 27, 2023
Last update
Jul 27, 2023

Study contacts

Ethel C Feleder, MD
principal investigator · FP Clinical Pharma S.R.L.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion